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Abstract
interest arises in new therapeutic alternatives such as cell transplantation, glial cell line-derived neuro-
trophic factor (GDNF) infusion, cell therapy or gene therapy. This review presents a general overview 
of current therapies used for PD and future lines of research, highlighting the role of gene therapy. The 
different gene therapy approaches for PD are revised. These include a symptomatic gene therapy, which 
which the glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) plays a fundamental 
role. Finally, the authors conclude that these lines of research are still far from clinical application.
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1. Introduction
-
disease. It is a pathology in which the nigrostriatal 
dopamine production. PD is characterized by mo-
tor symptoms such as freezing, postural instability, 
rigidity, or tremor, as well as non-motor symptoms, 
including anxiety, dementia and depression. In this 
review, the existing therapies for PD are described, 
with special emphasis on gene therapy, which has 
promising results to date. In gene therapy, viral 
vectors are employed to deliver genetic material 
that will modify the cause of the disease.
2. Therapeutic action for Parkinson’s 
disease 
The basis of the pathogenesis of PD is progressi-
ve degeneration of dopaminergic neurons in the ni-
grostriatal system. This makes PD a good target for 
regenerative medicine (1). 
Medicine for PD
2.1.1. Fetal nigral cell transplantation
Fetal nigral cells were transplanted to make new 
synaptic connections and to synthesize dopamine 
(2). At the outset of the 21st century, studies re-
-
sed dopamine uptake in elderly patients and some 
patients with tardive dyskinesia. Other studies re-
ported more optimistic aspects of fetal nigral cell 
transplantation using a cell suspension rather than 
solid tissue. Patients showed improvement in motor 
function and a reduced immune response in dyski-
nesia. Thus, fetal nigral cell transplantation might 
exert strong therapeutic effects for a long time with 
appropriate patient selection.
2.1.2. Infusion of glial cell line-derived neurotrophic 
factor (GDNF)
Alternatively, the intraparenchymal injection of 
GDNF can have important therapeutic effects, es-
pecially if the injection is at the intrastriatal level (3). 
was demonstrated as another hopeful therapeutic 
option for PD patients. Moreover, unilateral GDNF 
administration has been proved to improve bilate-
ral function.
2.1.3. Cell therapy 
One cell-based strategy is to transplant encapsula-
ted cells, which allows combining several geneti-
survived for up to 6 months in vivo with enough 
oxygen, nutrients, and a semi-permeable membra-
ne. The capsule protects cells from immunological 
rejection and tumor formation. Neural stem cells 
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(NSCs) and mesenchymal stem cells (MSCs) pro-
ved to be good candidates for this therapy, as the 
number of NSCs that survived in vivo was higher 
if they had previously been treated with GDNF. 
GDNF treatment increased the proportion of do-
paminergic neurons in MSCs. NSCs were mediated 
by secreted trophic factor. Embryonic stem cells 
(ESCs), the last alternative, induce neurons with a 
high proportion of dopaminergic neurons (4).
2.1.4. Gene therapy
and ex vivo. Direct gene delivery using vectors is 
the main characteristic of in vivo gene therapy. 
Herpes simplex virus (HSV), retrovirus, adenovi-
rus, and other non-viral vectors such as liposome 
The purposes of gene therapy are to increase 
local dopamine concentration, to exert neuropro-
tective/neurorestorative effects, to ameliorate the 
microenvironment of the dopaminergic system in-
volved in PD, and to normalize genetically abnor-
mal cells.
Around 80% of patients with PD are considered as 
idiopathic, whereas the remaining 20% cases are 
presumed to be genetic. In this section, the different 
PD are presented.
PD is a neurodegenerative disorder and the most 
common synucleinopathy (7). It is characterized by 
the accumulation of anomalous alpha-synuclein 
aggregates in the cytoplasm of neurons and glial 
cells. Alpha-synuclein is a fundamental component 
progression of PD. It is believed that alpha-synu-
“prion-like” properties that can spread throughout 
a network of neurons. This explains the progression 
of the disease from the basal ganglia to the neocor-
tex. Moreover, alpha-synuclein aggregates with 
beta-amyloid and tau. However, mutations respon-
-
nuclein gene. Highly penetrant mutations produ-
cing rare, monogenic forms of the disease have 
been discovered in singular genes such as SNCA. 
the most frequent (9), the rest are p.A30P, pE46K, 
autosomal-dominant PD-causing mutations with 
pleomorphic pathology and incomplete penetrance 
have been found in the gene encoding Leucine-rich 
repeat kinase 2 (LRRK2) (10). Six mutations in 
mutation and one splicing mutation) (11). This pro-
tein is involved in numerous cellular processes in-
cluding autophagy, cytoskeletal dynamics, kinase 
cascades, mitochondrial function and vesicular tra-
commonly known genetic cause of late-onset fami-
lial PD. Although the role of LRRK2 in cellular phy-
a better understanding of the pathogenesis of PD.
to the other autosomal dominant PD genes SNCA 
and LRRK2 through endosomes and vesicular tra-
ATP13A2, PLA2G6 and FBX07 have been shown to 
cause autosomal recessive PD and early-onset. Mu-
tations in PARK2 are the most frequent I of autoso-
mal recessive and early-onset PD due to a micro-
exon rearrangements, including both deletions and 
duplications. The pathology caused by PARK2 con-
sists of severe neuronal loss in the substantia nigra.
Mutations in PINK1 are the second most com-
mon cause of autosomal recessive PD (13). The 
1p36 and mutations in PINK1 are associated with 
this chromosome. PINK1 is located in the mitochon-
dria of cells and it helps protect mitochondria from 
malfunctioning during periods of cell stress. When 
this function is altered, cellular stress occurs, which 
seems to be related to the development of familial 
PD. PINK1 phosphorylates PARKIN2 to regulate 
mitophagy of damaged mitochondria.
Mutations producing rare forms of the disease 
have been discovered in gene DJ-1. This gene has 
been reported to protect dopaminergic cells against 
oxidative stress and to play a key role in maintai-
ning normal dopaminergic function in the nigros-
triatal pathway (14). Furthermore, DJ-1 seems to 
have chaperone activity and the ability to inhibit 
alpha-synuclein aggregation. It may be involved in 
transcriptional regulation of neuroprotective and 
anti-apoptotic genes and in the protection of neu-
rons from oxidative stress induced apoptosis.
Other rare, recessively inherited forms of PD 
are caused by mutations in three genes: ATP13A2, 
PLA2G6, y FBXO7. Mutations in GBA1, the gene 
encoding for the lysosomal enzyme glucocerebro-
sidase, cause Gaucher disease. Patients suffering 
from this disease have higher risk of developing 
PD and have symptoms associated with idiopathic 
PD. It was observed that mutation in gene GBA1 
lead to a loss of beta-glucocerebrosidase activity, 
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which causes lysosomal dysfunction and an increa-
sed substrate glucosylceramide accumulation. This 
led to review the link between the two diseases and 
the factors that cause monomeric alpha-synuclein 
to transform into neurotoxic forms and oligomeric 
aggregates that contribute to the progression of the 
Finally, it is worth noting the importance of 
the glial cell line-derived neurotrophic factor 
(GDNF) and neurturin for the survival of neuronal 
cells. These, as well as their receptors, were decrea-
sed and deregulated in patients with PD (9).
4. Gene therapy
Gene therapy is a therapeutic technique in which 
Its aim is to correct a genetic defect that often cau-
ses pathology. It can be performed by using viruses 
that carry these therapeutic molecules (16). Nowa-
days, there are two different gene therapy methods: 
symptomatic gene therapy and gene therapy fo-
gene therapy mainly refers to the transport of the 
dopa-decarboxylase enzyme, AADC (which trans-
forms levodopa into dopamine). This increases do-
with PD (18). This has been tested in animals where 
lower doses of levodopa meant higher doses with 
gene transport of AADC, producing an antiparkin-
sonian effect. Lentiviruses have also been used to 
transport tyrosine hydroxylase, AADC, and GTP 
cyclohydrolase, the combination of which results 
in dopamine. The combination of lentiviruses and 
dopamine has been tested in animals also having an 
antiparkinsonian effect.
 The second method focuses on GDNF and neu-
rturin. The gene transport of these trophic factors, 
such as neurturin, protects the nigrostriatal pa-
thway and the motor function. Nonetheless, this 
was not tested in humans but only in rodents and 
could be due to the extensive degeneration of the 
nigrostriatal system during treatment. Furthermo-
axonal transport mechanisms, so trophic factors are 
Gene therapy in PD is still a mystery, as no 
humans. Although a solution is possible, current-
ly gene therapy has only been used to treat motor 
symptoms. However, other symptoms such as psy-
chiatric ones would require a different type of gene 
therapy.
5. New therapeutic alternatives
Regarding the treatment of PD, the latest advances 
propose an imitation of nature. The distribution of 
neurotrophic factors using retroviruses is a very 
positive alternative to provide our target cells with 
these factors.
In this review we intend to address the main the-
rapies for the treatment of PD. It should be noted 
that, unlike the treatments introduced so far, this 
new perspective aims to act on the pathogenesis of 
instead of a merely symptomatic one. 
Neurotrophic factors are biological compounds 
that stimulate cell regeneration and, therefore, ease 
the healing process. They function by binding to 
cellular receptors and subsequently activating the 
cell signaling cascades that regulate mitosis, diffe-
rentiation, and apoptosis (20).
Neurturin (NRTN) is a natural analogue of neu-
rotrophic factors derived from the glial cell line 
(GDNFs), commonly used to attack dopaminergic 
neurons in PD animals (21). Its observed effects in-
clude delayed degeneration of neurons, selective 
protection of dopaminergic neurons, and general 
improvement of neural functioning. The adminis-
tration of this factor was tested by Gasmi et al in 
2007. Animal trials were conducted to achieve stria-
tal delivery of NRTN by using CeRe-120 (an ade-
no-associated virus type 2 - AAv2). Since then, the 
administration of this factor has been a very promi-
sing alternative for the treatment of PD.
in idiopathic PD, thanks to its integrating effect of 
grafts in the substantia nigra (22).
-
-
ins of patients with PD. Thus, it was thought that 
the administration of this factor would be a pro-
mising alternative in the treatment of the disease 
(23). Gobernado et al. administered LGF in rats and 
observer a possible neuroprotective activity. LGF 
is a hepatic mitogen that promotes proliferation of 
various cell types and facilitates tissue regenera-
tion. Upon peripheral application of LGF to the left 
striatum, sprouting of tyrosine hydroxylase-positi-
ve terminals and dopamine transporter expression 
was unilaterally increased. LGF also stimulated the 
phosphorylation and regulation of proteins critical 
for cell survival - including Bcl2 and Akt.
The aim of the administration of genes based on 
retroviruses is to deliver genes to the target cells, 
using viruses as means of transport. In this case, 
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packaged into these viral vectors, they convert their 
single stranded RNA into a double stranded DNA 
that can stably integrate into the host genome. The 
integrated vector, called provirus, undergoes repli-
cation and transcription in the host genome, pro-
ducing both viral mRNAs and packaged RNA. The 
integrated vector, called the provirus, undergoes 
replication and transcription in the host genome 
producing the viral mRNAs and the packaged RNA 
as well.
The importance of controlling the not-so-noble 
use of these systems, such as overexpression of ge-
nes, should be emphasized.
6. Conclusion
Today, we can classify PD as a pathology with 
a multifactorial etiology and a strong genetic in-
almost exclusively on the symptomatology. Howe-
ver, recent studies on gene therapy seek to provide 
an alternative that goes directly to the root of the 
problem. Through the arguments exposed in this 
review, it can be concluded that gene therapy may 
all the articles reviewed conclude this. There are sti-
-
netics, which appears to indicate a promising future 
for the treatment of PD.
-
terest in this article. 
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Growth Factor Potential function
Neurturin Will reduce the degeneration of neurons and enable neurons to function 
Neurotrophin
neuronal tissue
Epidermal Growth Factor Will upregulate the expression of EGF receptors and by extension increase 
afferent signals of dopaminergic neurons
Liver Growth Factor Will promote the proliferation and tissue regeneration in the substantia nigra 
pars compacta and other regions of dopaminergic neuron degeneration
Table 2: 
Therapeutic Action and Gene Therapy for Parkinson’s Disease
Annex I: Tables
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